Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1

Kidney International

Volumn 51, Issue 6, 1997, Pages 1818-1830

  Duymelinck, Carla ^a   Dauwe, Simonne E H ^a   Nouwen, Etienne J ^a   De Broe, Marc E ^a   Verpooten, Gert A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030916366     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.249     Document Type: Article

References (65)

1. REMUZZI G, DIEPERINK H: Specific drugs-immunosuppression: Cyclosporine/FK506, in Clinical Nephrotoxicity: Renal Injury from Drugs and Chemicals, edited by BENNETT WM, DE BROE ME, PORTER GA, VERPOOTEN GA, Dordrecht, Kluwer Academic Publishers Group (in press)
2. BENNET WM, NORMAN DJ: Action and toxicity of cyclosporine. Annu Rev Med 37:215-224, 1986
3. MYERS BD: Cyclosporine nephrotoxicity. Kidney Int 30:964-974, 1986
4. MYERS BD, ROSS J, NEWTON L, LUETSCHER J, PEREROTH M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699-705, 1984
5. KLINTMALM G, SUNDELIN B, BOHMAN S-O, WILCZEK H: Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporine treatment: Beneficial effect of low doses in early post-transplantation period. Lancet i:950-953, 1984
6. MIHATSCH MJ, THIEL G, SPICHTIN HP, OBERHOLZER M, BRUNNER FP, HARDER F, OLIVIERI V, BREMER R, RYFFEL B, STÖCKLIN E, TORHORST J, GUDAT F, ZOLLINGER HU, LOERTSCHER R: Morphological findings in kidney transplants after treatment with cyclosporine. Transplant Proc 15:2821-2835, 1983
7. YOUNG BA, BURDMANN EA, JOHNSON RJ, ALPERS CE, GIACHELLI CM, ENG E, ANDOH T, BENNETT WM, COUSER WG, LINDSEY J, DUYN J: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439-448, 1995
8. ROSEN S, GREENFELD, Z, BREZIS M: Chronic cyclosporine-induced nephropathy in the rat. Transplantation 49:445-452, 1990
9. GILLUM DM, TRUONG L, TASBY J, MIGLIORE P, SUKI WN: Chronic cyclosporine nephrotoxicity. Transplantation 46:285-292, 1988
10. JACKSON NM, HSU C-H, VISSCHER GE, VENKATACHALAM MA, HUMES HD: Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. J Pharmacol Exp Ther 242:749-756, 1987
11. DIEPERINK H, KEMP E, STARKLINT H: Cyclosporine A in high dosages induces renal interstitial fibrosis in the rat. Transplant Proc 20:525-527, 1988
12. GERKENS JF, BHAGWANDEEN SB, DOSEN PJ, SMITH AJ: The effect of salt intake on cyclosporine-induced impairment of renal function in rats. Transplantation 38:412-417, 1984
13. WHITING PH, CUNNINGHAM C, THOMSON AW, SIMPSON JG: Enhancement of high dose cyclosporin A toxicity by furosemide. Biochem Pharmacol 33:1075-1079, 1984
14. VASSALLI J-D, SAPPINO A-P, BELIN D: The plasminogen activator/plasmin system. J Clin Invest 88:1067-1072, 1991
15. SCULLY MF: Plasminogen activator-dependent pericellular proteolysis. Br J Haematol 79:537-543, 1991
16. BALLANTYNE CM, PODET EJ, PATSCH WP, HARATI Y, APPEL V, GOTTO AM, YOUNG JB: Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 262:53-56, 1989
17. DRUËCKE TB, ABDULMASSIH Z, LACOUR B, BADER C, CHEVALIER A, KREIS H: Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 39(Suppl 31):S24-S28, 1991
18. RAINE AEG, CARTER R, MANN JI, MORRIS PJ: Adverse effects of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 3:458-463, 1988
19. SCHORN TF, KLIEM V, BOJANOVSKI D, REPP H, BUNZENDAHL H, FREI U: Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transplant Int 4:92-95, 1991
20. WEBB AT, PLANT M, REAVELEY D, O'DONNELL M, LUCK VA, O'CONNOR B, SEED M, BROWN EA: Lipid and lipoprotein(a) concentrations in renal transplant recipients. Nephrol Dial Transplant 7:636-641, 1992
21. EDWARDS BD, BHATNAGAR D, MACKNESS MI, GOKAL R, BALLARDIE FW, CHALMERS RJG, DURRINGTON PN: Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Quart J Med 88:109-113, 1995
22. KUSTER GM, DREXEL H, BLEISCH JA, RENTSCH K, PEI P, BINSWANGER U, AMANN FW: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 57:1479-1483, 1994
23. VERPOOTEN GA, COOLS FJ, VAN DER PLANCKEN MG, BEDERT LC, CLAES R, VAN GAAL LF, DE BROE ME: Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 11:347-351, 1996
24. LÓPEZ-MIRANDA J, VILELLA E, PÉREZ-JIMÉNEZ F, ESPINO A, JIMÉNEZ-PEREPÉREZ JA, MASANA L, TURNER PR: Low-density lipoprotein metabolism in rats treated with cyclosporine Metabolism 42:678-683, 1993
25. SUTHERLAND WHF, WALKER RJ, BALL MJ, STAPLEY SA, ROBERTSON MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 48:227-236, 1995
26. APANAY DC, NEYLAN JF, RAGAB MS, SGOUTAS DS: Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 58:663-669, 1994
27. WITZTUM JL, STEINBERG D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991
28. LEVI M, WIMINK J, BÜLLER HR, SURACHNO J, TEN CATE JW: Impaired fibrinolysis in cyclosporin-treated renal transplant patients. Transplantation 54:978-983, 1992
29. TREMOLI E, CAMERA M, MADERNA P, SIRONI L, PRATI L, COLLI S, PIOVELLA F, BERNINI F, CORSINI A, MUSSONI L: Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. A LDL receptor independent phenomenon. Arterioscler Thromb 13:338-346, 1993
30. STIKO-RAHM A, WIMAN B, HAMSTEN A, NILSON J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very-low-density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
31. EMESON EE, SHEN M-L: Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol 142: 1016-1915, 1993
32. SHIHAB FS, ANDOH TF, TANNER AM, NOBLE NA, BORDER WA, FRANCESCHINI N, BENNETT WM: Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 49:1141-1151, 1996
33. GARCIA RL, COLTRERA MD, GOWN AM: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 134:733-739, 1989
34. WOOLLET GR, BARCLAY AN, PUKLAVEC M, WILLIAMS AF: Molecular and antigenic heterogeneity of the rat leukocyte-common antigen from thymocytes and T and B lymphocytes. Eur J Immunol 15:168-173, 1985
35. DIJKSTRA CD, DÖPP EA, JOLING P, KRAAL G: The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2, and ED3. Immunology 54:589-599, 1985
36. BRIDEAU RJ, CARTER PB, MCMASTER WR, MASON DW, WILLIAMS AF: Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur J Immunol 10:609-615, 1980
37. MCMASTER WR, WILLIAMS AF: Identification of Ia glycoproteins in rat thymus and purification from rat spleen. Eur J Immunol 9:426-433, 1979
38. DECLERCK PJ, ALESSI M-C, VERSTREKEN M, KRUTTHOF EKO, JUHANVAGUE I, COLLEN D: Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71:220-225, 1988
39. VERPOOTEN GA, WYBO I, PATTYN VM, HENDRIX PG, GIULIANO RA, NOUWEN EJ, ROELS F, DE BROE ME: Cyclosporine nephrotoxicity: Comparative cytochemical study of rat kidney and human allograft biopsies. Clin Nephrol 25(Suppl 1):S18-S22, 1986
40. KOPP JB, KLOFMAN PE: Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1:162-179, 1990
41. KAPLAN R, AYNEDJIAN HS, SCHLONDORFF D, BANK N: Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest 86:1707-1714, 1990
42. GUPTA SK, BENET LZ: High-fat meals increase the clearance of cyclosporine. Pharmaceutical Res 7:46-48, 1990
43. HORTON JD, CUTHBERT JA, SPADY DK: Regulation of hepatic 7α-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem 270:5381-5387, 1995
44. VLAHCEVIC ZR, HEUMAN DM, HYLEMON PB: Regulation of bile acid synthesis. Hepatology 13:590-600, 1991
45. CHOICE E, MASIN D, BALLY MB, MELOCHE M, MADDEN TD: Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60:1006-1011, 1995
46. EDDY AA, LIU E, MCCULLOCH L: Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 50:1139-1149, 1996
47. SHIVJI MKK, KENNY MK, WOOD RD: Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374, 1992
48. KONE BC, RACUSEN LC, WHELTON A, SOLEZ K: Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat. Clin Nephrol 25(Suppl 1):S171-S174, 1986
49. LAN HY, MU W, NIKOLIC-PATERSON DJ, ATKISS RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven healing to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97-102, 1995
50. KOVACS EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 12:17-23, 1991
51. AYA N, YOSHIOKA K, MURAKAMI K, HINO S, OKADA K, MATSUO O, MAKI S: Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J Pathol 166:289-295, 1992
52. RONDEAU E, MOUGENOT B, LACAVE R, PERALDI MN, KRUITHOF EKO, SRAER JD: Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 33:55-60, 1990
53. EDDY AA, GIACHELLI CM, MCCULLOCH L, LIU E: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546-1557, 1995
54. TOMOOKA S, BORDER WA, MARSHALI BC, NOBLE NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992
55. BARNES JL, MITCHELL RJ, TORRES ES: Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. J Histochem Cytochem 43:895-905, 1995
56. KEETON M, EGUCHI Y, SAWDEY M, AHN C, LOSKUTOFF DJ: Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 142:59-70, 1993
57. GINSBERG D, ZEHEB R, YANG AY, RAFFERTY UM, ANDREASEN PA, NIELSEN L, DANO K, LEBO RV, GELEHRTER TD: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78:1673-1680, 1986
58. HEKMAN CM, LOSKUTOFF DJ: Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581-11587, 1985
59. DEBROCK S, DECLERCK PJ: Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett 376:243-246, 1995
60. MADSEN KM, BRENNER BM: Structure and function of the renal tubule and interstitium, in Renal Pathology, edited by TISCHER CC, BRENNER BM, Philadelphia, JB Lippineott Company, 1989, pp 1518-1551
61. NYKJAER A, PETERSEN CM, MOLLER B, JENSEN PH, MOESTROP SK, HOLTET TL, ETZERODT M, THOGERSEN HC, MUNCH M, ANDREASEN PA, GLIEMANN J: Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. J Biol Chem 267:14543-14546, 1992
62. CHRISTENSEN EI, NIELSEN S, MOESTRUP SK, BORRE C, MAUNSBACH AB, DE HEER E, RONCO P, HAMMOND TG, VERROUST P: Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 66:349-364, 1995
63. PREISSNER KT: Structure and biological role of vitronectin. Annu Rev Cell Biol 7:275-310, 1991
64. WANG Y, THOMPSON EM, WHAWELL SA, FLEMING KA: Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys. J Pathol 169:445-450, 1993
65. EDDY AA: Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Kidney Int 49(Suppl 54):S49-S54, 1996